← Back to Clinical Trials
Recruiting NCT07230210

NCT07230210 Smart Tech-Based Nutrition and Exercise for Sarcopenia Risk.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07230210
Status Recruiting
Phase
Sponsor HSIAO MEI LAN
Condition Sarcopenia
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-12-03
Primary Completion 2028-12-31

Trial Parameters

Condition Sarcopenia
Sponsor HSIAO MEI LAN
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2025-12-03
Completion 2028-12-31
Interventions
The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia. Intervention: Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care. Purpose: The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia. Expected Benefit: The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults

Eligibility Criteria

Inclusion Criteria Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia. No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments. Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete informed consent and daily logs. Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes). Exclusion Criteria Self-reported functional impairment in any limb. Requires assistance from a wheelchair, walker, or cane for ambulation. Has an implanted cardiac pacemaker. Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology